Summary: MAPS is featured in an article on the front page of today’s edition of The New York Times!
Reporter Andrew Jacobs profiles MAPS Founder and Executive Director Rick Doblin, Ph.D., and highlights the success of MAPS’ first Phase 3 study of MDMA-assisted therapy for PTSD, the results of which were published in Nature Medicine earlier today.
“After decades of demonization and criminalization,” explains Jacobs, “psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.”
Originally appearing here.
